International research project PREVFNAIT
In October 2013 the Institute of Hematology and Transfusion Medicine ( IHTM) in collaboration with the University of Tromsø (Norway ) has started a 3-year research project PREVFNAIT entitled " Prevention of alloimmune thrombocytopenia in Polish fetuses and newborns ". The project is dedicated to HPA- 1 antigen incompatibility between mother and fetus which may lead to the production of antibodies against the fetal HPA-1a antigen. The project covers the issues of :
• early detection, of fetal neonatal alloimmuno thombocytopenia in Polish pregnant women,
• prevention of fetal neonatal alloimmuno thombocytopenia,
• exploration of immunological mechanisms of fetal neonatal alloimmuno thombocytopenia,
The project has received funding from the Polish-Norwegian Research Programme operated by the National Centre for Research and Development under the Norwegian Financial Mechanism 2009-2014 in the frame of Project Contract No Pol-Nor/203111/69/2013
PREVFNAIT received funding in the first round (269 applications were submitted, 68 projects received funding; 47 in the first round , 20 in the second round and 1 following appeal Of the submitted 269 applications 68 projects received funding 75 were related to health and 14 received funding.
Assumptions and aims of the grant
Fetal/neonatal thrombocytopenia (FNAIT) affects 4,000 foetuses and new-borns a year in EU-27 and may result in intracranial haemorrhage, foetal death or lifelong disability. FNAIT most commonly develops after a mother negative for the platelet antigen HPA-1a has been immunized by her HPA-1a positive foetus. Because HPA-1a immunization and FNAIT are highly underdiagnosed in Poland and elsewhere, FNAIT remains to be inadequately prevented and treated.
PREVFNAIT–This project involves typing of 30,000 pregnant women in Poland in order to identify an estimated 600 HPA-1s negative mothers at risk of being immunized or cause FNAIT. These mothers are subjected to thorough genetic and biomarker analyses, intensified surveillance and timely treatment of FNAIT if required.
Objectives–The primary objectives are to
1/ Demonstrate feasibility of low-cost HPA-1 typing in Poland via performance and cost analyses;
2/ Determine the prevalence of the HPA-1bb genotype, HPA-1a immunization, FNAIT and of factors predisposing for FNAIT in pregnant women in Poland;
3/ Determine the predictive value of new/suspected/known biomarkers of FNAIT;
4/ Demonstrate cost-effectiveness of HPA-1 typing and timely prevention/treatment of FNAIT.
5/ Establish a biobank with time-course samples and clinical information from 600 HPA-1bb women for use in future research and collaborations.
Impact–Short term, the project will ensure optimal FNAIT prevention in or treatment of 600 HPA-1a negative Polish women. Long term, the project promotes obligatory HPA-1 typing and prevention of FNAIT in combination with a prophylaxis.
Institute of Hematology and Transfusion Medicine, Warsaw, Poland
Prof. Ewa Brojer - Principal Investigator, Chairman of the Steering Commitee
Prof. Krystyna Maślanka - Member of the Steering Commitee
Dr Małgorzata Uhrynowska - Member of the Steering Commitee
Dr Katarzyna Guz
Dr Agnieszka Orzińska
Project partner Universitetet in Tromsø
Prof. Anne Husebekk - Member of the Steering Commitee
Dr Gerd Berge - Member of the Steering Commitee
Dr Maria Therese Ahlén - Member of the Steering Commitee
Dr Eirin Listau Bertelsen
Dr Kristine Tollefsen